Suppr超能文献

使用WST11-血管靶向光动力(VTP)疗法确定实现局限性前列腺癌微创聚焦消融的最佳药物剂量和光剂量指数。

Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.

作者信息

Moore Caroline M, Azzouzi Abel-Rahmene, Barret Eric, Villers Arnauld, Muir Gordon H, Barber Neil J, Bott Simon, Trachtenberg John, Arumainayagam Nimalan, Gaillac Bertrand, Allen Clare, Schertz Avigdor, Emberton Mark

机构信息

Division of Surgery and Interventional Science, University College London, London, UK.

CHU, Angers, France.

出版信息

BJU Int. 2015 Dec;116(6):888-96. doi: 10.1111/bju.12816. Epub 2015 Apr 21.

Abstract

OBJECTIVE

To determine the optimal drug and light dose for prostate ablation using WST11 (TOOKAD Soluble) for vascular-targeted photodynamic (VTP) therapy in men with low-risk prostate cancer.

PATIENTS AND METHODS

In all, 42 men with low-risk prostate cancer were enrolled in the study but two who underwent anaesthesia for the procedure did not receive the drug or light dose. Thus, 40 men received a single dose of 2, 4 or 6 mg/kg WST11 activated by 200 J/cm light at 753 nm. WST11 was given as a 10-min intravenous infusion. The light dose was delivered using cylindrical diffusing fibres within hollow plastic needles positioned in the prostate using transrectal ultrasonography (TRUS) guidance and a brachytherapy template. Magnetic resonance imaging (MRI) was used to assess treatment effect at 7 days, with assessment of urinary function (International Prostate Symptom Score [IPSS]), sexual function (International Index of Erectile Function [IIEF]) and adverse events at 7 days, 1, 3 and 6 months after VTP. TRUS-guided biopsies were taken at 6 months.

RESULTS

In all, 39 of the 40 treated men completed the follow-up. The Day-7 MRI showed maximal treatment effect (95% of the planned treatment volume) in men who had a WST11 dose of 4 mg/kg, light dose of 200 J/cm and light density index (LDI) of >1. In the 12 men treated with these parameters, the negative biopsy rate was 10/12 (83%) at 6 months, compared with 10/26 (45%) for the men who had either a different drug dose (10 men) or an LDI of <1 (16). Transient urinary symptoms were seen in most of the men, with no significant difference in IPSS score between baseline and 6 months after VTP. IIEF scores were not significantly different between baseline and 6 months after VTP.

CONCLUSION

Treatment with 4 mg/kg TOOKAD Soluble activated by 753 nm light at a dose of 200 J/cm and an LDI of >1 resulted in treatment effect in 95% of the planned treatment volume and a negative biopsy rate at 6 months of 10/12 men (83%).

摘要

目的

确定使用WST11(图卡德可溶性剂)进行血管靶向光动力(VTP)治疗低风险前列腺癌男性患者时前列腺消融的最佳药物和光剂量。

患者与方法

共有42例低风险前列腺癌男性患者纳入本研究,但其中2例在手术过程中接受麻醉的患者未接受药物或光剂量。因此,40例患者接受了2、4或6mg/kg的WST11单剂量,由753nm波长的200J/cm光激活。WST11通过静脉输注10分钟给药。光剂量通过置于前列腺内的中空塑料针内的圆柱形扩散光纤输送,使用经直肠超声(TRUS)引导和近距离放射治疗模板。在7天时使用磁共振成像(MRI)评估治疗效果,并在VTP后7天、1、3和6个月评估泌尿功能(国际前列腺症状评分[IPSS])、性功能(国际勃起功能指数[IIEF])和不良事件。在6个月时进行TRUS引导下的活检。

结果

40例接受治疗的患者中,39例完成了随访。第7天的MRI显示,WST11剂量为4mg/kg、光剂量为200J/cm且光密度指数(LDI)>1的患者治疗效果最佳(达到计划治疗体积的95%)。在接受这些参数治疗的12例患者中,6个月时活检阴性率为10/12(83%),而药物剂量不同(10例患者)或LDI<1(16例患者)的患者活检阴性率为10/26(45%)。大多数患者出现短暂的泌尿症状,VTP后基线与6个月时IPSS评分无显著差异。VTP后基线与6个月时IIEF评分无显著差异。

结论

使用753nm波长的光以200J/cm的剂量激活4mg/kg图卡德可溶性剂进行治疗,LDI>1时,95%的计划治疗体积产生了治疗效果,6个月时10/12例患者(83%)活检阴性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验